Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Summit Therapeutics NASDAQ:SMMT on Sunday said ivonescimab significantly extended survival compared with Merck’s NYSE:MRK Keytruda in a late-stage lung cancer trial conducted by its partner Akeso OTC:AKESF in China.Ivonescimab reduced the risk of death by 27% compared with Keytruda, also known as p…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.